Penumbra Inc. ((PEN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Penumbra Inc. is conducting a study titled ‘STRIKE-PE: A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism.’ The study aims to assess the long-term safety and effectiveness of the Indigo Aspiration System in treating pulmonary embolism (PE), a serious condition that can lead to significant health complications. This study is significant as it seeks to provide real-world data on the functional outcomes and safety of this treatment method.
The intervention being tested is the Indigo Aspiration System, a medical device designed to remove blood clots in patients suffering from acute pulmonary embolism. Its purpose is to improve patient outcomes by effectively treating PE with minimal risk.
The study is observational in nature, following a cohort of patients over time to gather data on the device’s performance and safety. It is set up as a prospective study, meaning it will follow participants forward in time to observe outcomes.
The study began on February 26, 2021, and is currently recruiting participants. The last update was submitted on July 21, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and ensuring timely data collection.
The market implications of this study are significant for Penumbra Inc., as positive results could enhance investor confidence and potentially boost the company’s stock performance. In the competitive medical device industry, successful innovation in treating pulmonary embolism could position Penumbra as a leader, influencing investor sentiment positively.
The study is ongoing, and further details are available on the ClinicalTrials portal.